To report results at week 208, including a 104-week masked extension, of the EMPA-REG H2H-SU trial in patients with type 2 diabetes with inadequate glycaemic control on metformin, in which empagliflozin 25 mg given for 104 weeks provided a sustained reduction in glycated haemoglobin (HbA1c) with a small but statistically significant benefit vs glimepiride, sustained reductions in weight and blood pressure, and low risk of hypoglycaemia. Conclusions: In patients with type 2 diabetes, empagliflozin 25 mg as add-on to metformin for 208 weeks reduced HbA1c with a significantly lower risk of hypoglycaemia and a significantly smaller proportion of patients receiving rescue therapy compared with glimepiride.
| INTRODUCTION
Type 2 diabetes is associated with multiple pathophysiological defects that create challenges for its long-term management. 1 Metformin is the recommended first-line therapy for type 2 diabetes, but secondline therapy is often required to achieve or maintain glycaemic control. 1 Sulphonylureas are commonly used as second-line therapy, but are associated with low durability, hypoglycaemia, and weight gain. 1 Empagliflozin is a potent and selective inhibitor of sodium-glucose co-transporter-2 (SGLT2). In phase III trials, empagliflozin 10 and 25 mg used as monotherapy or as add-on to commonly used glucoselowering medications significantly reduced glycated haemoglobin (HbA1c), weight and blood pressure in patients with type 2 diabetes, and were well tolerated, with a low risk of hypoglycaemia. [2] [3] [4] [5] [6] [7] [8] More recently, the results of the EMPA-REG OUTCOME trial have shown that, in patients with type 2 diabetes and established cardiovascular disease, empagliflozin given in addition to standard of care reduced cardiovascular outcomes, renal outcomes and mortality. 9, 10 The EMPA-REG H2H-SU trial was a 104-week trial with a double-blind 104-week extension undertaken to compare the efficacy and safety of empagliflozin with the sulphonylurea glimepiride as addon to metformin in patients with type 2 diabetes. 11 At week 104, empagliflozin as add-on to metformin provided a sustained reduction in HbA1c, with a small yet significantly superior difference compared with glimepiride, sustained reductions in weight and blood pressure and a low risk of hypoglycaemia. 12 In the present paper, we report the results at week 208 including the 104-week double-blind extension period of the EMPA-REG H2H-SU trial.
| RESEARCH DESIGN AND METHODS

| Study design
EMPA-REG H2H-SU was a phase III randomized, double-blind, activecontrolled, parallel-group, 104-week trial with a 104-week doubleblind extension period. 11 It was pre-specified that unblinded analyses of data would be performed at weeks 52 and 104, which comprised the primary and key secondary endpoints, and at week 208. A total of 698 patients per group were needed to provide a power of ≥95% to show non-inferiority, based on a margin of 0.3%, for the primary endpoint at weeks 52 and 104 if the true treatment effect is 0.05%
(in favour of glimepiride) and SD is 1.2%. 11, 12 The trial was registered Safety was analysed in the treated set (patients who received ≥1
| Inclusion and exclusion criteria
dose of study drug). The proportion of patients with confirmed hypoglycaemic adverse events was analysed using a logistic regression model including treatment and continuous baseline HbA1c. Time to first confirmed hypoglycaemic adverse event was analysed using Kaplan-Meier estimates. Incidence rates for adverse events per 100 patient-years were calculated to adjust for differences in study drug exposure between treatment groups. Changes from baseline in eGFR and lipid variables over 208 weeks were analysed using MMRM analyses (including values after the initiation of rescue medication).
Changes in eGFR at last value on treatment and follow-up were analysed using ANCOVA in patients from the FAS who had a measurement at follow-up.
| RESULTS
In total, 1549 patients were randomized at 173 sites in 23 countries.
Of these, 1545 were treated, 1125 entered the extension period The exposure-adjusted incidence rates of adverse events, drugrelated adverse events, and adverse events leading to discontinuation were higher in patients treated with glimepiride than empagliflozin (Table 1) . Events consistent with genital infection and urinary tract infection were more common in patients treated with empagliflozin (Table 1) . Pyelonephritis was reported in 2 patients (0.3%) in each treatment group. Urosepsis was reported in 1 patient (0.1%) treated with glimepiride and none treated with empagliflozin. The incidence of bone fractures was similar between treatment groups. Events consistent with volume depletion occurred at a higher rate in patients treated with empagliflozin than glimepiride. There were no cases of diabetic ketoacidosis. A greater proportion of patients treated with glimepiride had adjudicated cardiovascular events but the number of events was small (Table S5 , Supporting Information).
In patients treated with empagliflozin, mean eGFR was maintained over the 208-week treatment period and increased to slightly above baseline at the follow-up visit, while mean eGFR declined in patients treated with glimepiride ( Figure 3 ). There were no clinically relevant differences between empagliflozin and glimepiride in changes in other laboratory variables (Table S6 , Supporting Information).
| DISCUSSION
In this head-to-head trial of therapies given as add-on to metformin, 12 empagliflozin provided a sustained reduction in HbA1c, with a small yet significant benefit vs glimepiride at week 104. In the present study, we have shown that a modest numerical advantage in mean change from baseline in HbA1c with empagliflozin vs glimepiride was maintained after a 104-week extension period. Although the differences in mean changes in HbA1c at week 208 were small, fewer patients in the empagliflozin group used rescue therapy and it tended to be used later. A higher proportion of patients on empagliflozin than glimepiride achieved a clinically relevant reduction in HbA1c at week 208 without receiving rescue medication. Further, empagliflozin was associated with a much lower hypoglycaemia risk. This constitutes a clinically meaningful advantage of empagliflozin over glimepiride, as hypoglycaemia poses serious health risks and can be a significant barrier to achieving glycaemic control. 13 Between week 104 and week 208, mean HbA1c gradually increased toward baseline levels in both treatment groups. This may be related to the amount of missing data at week 208 and the use of rescue medication over the study, as only 48% and 31% of patients in the empagliflozin and glimepiride groups, respectively, had an HbA1c value at week 208 and had not used rescue medication. We per- showed that empagliflozin significantly reduced postprandial glucose, accompanied by a reduction in insulin, and reduced 24-hour mean glucose measured using continuous glucose monitoring.
14 In addition to improving glycaemic control, empagliflozin led to clinically relevant reductions in weight and blood pressure, which were sustained over the 208-week treatment period. In patients with type 2 diabetes, weight loss can be associated with improvements in quality of life 15 and better adherence to medication. 16 Treatment with empagliflozin was associated with a reduction in visceral adipose tissue, which has been associated with cardiometabolic abnormalities such as insulin resistance and dyslipidaemia. 17 Empagliflozin 25 mg for 208 weeks was well tolerated, with an adverse event profile consistent with previous trials. 18 Events consistent with genital infection, urinary tract infection, or volume depletion occurred more frequently in patients treated with empagliflozin than glimepiride. The number of patients with cardiovascular events in this trial was too small to allow conclusions to be drawn, but a metaanalysis of data from eight placebo-controlled clinical trials of empagliflozin, involving 11 292 patients with type 2 diabetes at low/medium or high cardiovascular risk, showed that empagliflozin was associated with a reduced risk of 3-point MACE (major adverse cardiovascular events: composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke). 19 Results from the EMPA-REG OUT-COME trial in patients with type 2 diabetes and established cardiovascular disease showed that empagliflozin given in addition to standard of care reduced the risk of 3-point MACE, driven by a 38% reduction in the risk of cardiovascular death. 9 Renal function (eGFR) in the empagliflozin group was maintained over 208 weeks and rose to slightly above the baseline level at the follow-up visit. These observations are consistent with the results of the EMPA-REG OUTCOME trial, in which the initial decrease in eGFR with empagliflozin was reversed after cessation of study drug and mean eGFR was significantly higher compared with placebo at the follow-up visit. 10 This pattern of change in eGFR suggests that the initial decrease in GFR in patients treated with empagliflozin is attributable to haemodynamic effects that are reversed after treatment cessation.
A strength of the 104-week extension of this study is that patients continued to receive the treatment allocated at randomization in a double-blind manner. Limitations include the amount of missing data at week 208, the relatively small numbers of patients included in the mean daily glucose, postprandial glucose, and body composition substudies, and that the number of outcomes and populations analysed may have increased the probability of a falsepositive result. We regard the protocol-defined limit in the uptitration of glimepiride to 4 mg per day, half the maximum daily dose, as a strength rather than a weakness of the study, as the glycaemic benefits of sulphonylureas are nearly fully realized at this dose, and 
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